AstraZeneca Pharmaceuticals LP
NEWS
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
AstraZeneca aims to harness VaxEquity’s saRNA platform for use with its own therapeutic programs and intends to widely use it on up to 26 different drug targets.
MiroBio’s pipeline involves checkpoint receptor pathways, not for immuno-oncology indications, but for the treatment of autoimmune diseases.
Patients with different forms of breast cancer could soon have different treatment options following multiple presentations at the European Society of Medical Oncology meeting.
Lung cancer is a particularly difficult cancer to treat, but several companies presented very promising data at this year’s European Society of Medical Oncology (ESMO) Congress 2021.
COVID-19 remains relentless in challenging the community as it continues to evolve. Here are some of the top news for the week.
Biopharma companies big and small are presenting exciting clinical studies at the European Society for Medical Oncology Congress 2021.
A recent study suggests that about one-third of cancer indications with Accelerated Approval pathways are still on product labels without follow-up studies confirming their benefits.
JOBS
IN THE PRESS